Its compact four-amino acid structure facilitates straightforward handling across a broad range of in vitro experimental formats
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
This balanced approach helps patients experience more than temporary relief
A 2026 UK review of the February 2025 Nature Aging DO-HEALTH trial (1 g/day slowed biological ageing ~4 months), the Framingham red-blood-cell DHA data (~49% lower Alzheimers risk in the top group), the midlife hippocampal-volume study, the ~20% lower dementia risk from dietary omega-3, the APOE4 timing question and the honest atrial-fibrillation caveat with high-dose fish oil versus Dihexas unproven HGF/c-Met synaptogenesis, and why oily fish comes first, not a peptide Read the full review NewNutrition, Diet & Cognitive Neuroscience 4 July 2026 Dihexa for Ultra-Processed Food Brain Fog: UPF, Cognition & the HGF/c-Met Question Can Dihexa undo ultra-processed food brain fog
It reduces inflammation and protects normal cell function by scavenging free radicals
It usually fades within a day or two, and proper technique helps minimize it